Share

April 2016; 6 (2) CommentaryOpen Access

Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients

Dennis N. Bourdette, Daniel M. Hartung, Ruth H. Whitham
First published December 10, 2015, DOI: https://doi.org/10.1212/CPJ.0000000000000208
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2255

Share

Article Information

vol. 6 no. 2 177-182
DOI: 
https://doi.org/10.1212/CPJ.0000000000000208
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received June 16, 2015
  • Accepted October 7, 2015
  • First Published December 10, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Dennis N. Bourdette, MD,
    2. Daniel M. Hartung, PharmD, MPH and
    3. Ruth H. Whitham, MD
  1. Dennis N. Bourdette, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Current Neurology and Neuroscience Reports, Section Editor, 2008-present; Autoimmune Diseases, Associate Editor, 2009-present; Neurology, Member Editorial Board, 2013-present present. I receive no compensation for any of these activities.

    Patents:

    1. I have a use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin. I have a patent pending for a thyromimetic drug for stimulating remyelination in multiple sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant to Teva Neurosciences within the past 24 months; Biogen; Genentech

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. Department of Veterans Affairs/Rehabilitation R&D, Merit Review, 1/1/12-12/31/15 National MS Society April 2015- present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Daniel M. Hartung, PharmD, MPH and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Providence Health Systems. Consulting services

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) AHRQ, 1K12HS019456-01; Career development award 2010 - 2013 (2) CDC/NIDA, 1U01CE002500-01; Principal investigator, 2014 - 2016 (3) AHRQ, 1R18HS024227-01; Principal investigator, 2015-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ruth H. Whitham, MD
    4. Scientific Advisory Boards:

    1. I am a member of the data safety monitoring board for two clinical trials for treatment of neuromyelitis optica, sponsored by Chugai Pharmaceutical Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (DNB, RHW), Oregon Health & Science University, Portland; Multiple Sclerosis Center of Excellence West (DNB, RHW), VA Portland Health Care System, OR; and The College of Pharmacy (DMH), Oregon State University/Oregon Health & Science University, Portland.
  1. Correspondence to:
    bourdett{at}ohsu.edu
View Full Text

Article usage

Article usage: December 2015 to December 2021

AbstractFullPdfSource
Dec 20152952513Highwire
Jan 20161726113Highwire
Feb 201682326Highwire
Mar 2016123227Highwire
Apr 20163545572Highwire
Apr 2016010910pmc
May 20162071364Highwire
May 2016017616pmc
Jun 20161301811Highwire
Jun 20160719pmc
Jul 201683915Highwire
Jul 20160274pmc
Aug 2016571424Highwire
Aug 20160299pmc
Sep 2016891214Highwire
Sep 20160192pmc
Oct 201646914Highwire
Oct 20160255pmc
Nov 20165679Highwire
Nov 20160393pmc
Dec 201675127Highwire
Dec 20160313pmc
Jan 201759914Highwire
Jan 20170258pmc
Feb 2017801316Highwire
Feb 201705311pmc
Mar 2017171116Highwire
Mar 20170808pmc
Apr 20171141710Highwire
Apr 201784764pmc
May 20176385Highwire
May 201746781pmc
Jun 20176224Highwire
Jun 201763745pmc
Jul 20173658Highwire
Jul 201725154pmc
Aug 20173058Highwire
Aug 2017124647pmc
Sep 201711211Highwire
Sep 201726788pmc
Oct 20171742Highwire
Oct 201766774pmc
Nov 201717108Highwire
Nov 201775765pmc
Dec 20178244Highwire
Jan 201852715Highwire
Feb 201811356Highwire
Mar 201824115Highwire
Apr 20183277Highwire
Apr 201875258pmc
May 201844517Highwire
Jun 201805015Highwire
Jun 201844249pmc
Jul 201823611Highwire
Aug 20183343Highwire
Aug 201814350pmc
Sep 20183317Highwire
Oct 20183434Highwire
Nov 20182498Highwire
Dec 201831176Highwire
Jan 201931157Highwire
Feb 2019811610Highwire
Mar 2019819718Highwire
Apr 2019521213Highwire
May 20191014313Highwire
Jun 2019621320Highwire
Jul 201943877Highwire
Aug 201918515Highwire
Sep 2019482910Highwire
Oct 201947163Highwire
Nov 2019751911Highwire
Dec 2019525114Highwire
Jan 202033013Highwire
Feb 2020920612Highwire
Mar 2020934610Highwire
Apr 202012687Highwire
May 202013269Highwire
Jun 20201523Highwire
Jul 2020171Highwire
Aug 20203129Highwire
Sep 20202103Highwire
Oct 2020111814Highwire
Nov 2020725511Highwire
Dec 202034006Highwire
Jan 202121115Highwire
Feb 2021284Highwire
Mar 2021778Highwire
Apr 20213167Highwire
May 202141610Highwire
Jun 2021389Highwire
Jul 2021486Highwire
Aug 2021113824Highwire
Sep 20219697Highwire
Oct 2021631426Highwire
Nov 2021611622Highwire
Dec 202189136Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me